Leukemia Cell Articles & Analysis

3 news found

Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits

Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - Senti Biosciences, Inc. ...

Jun. 9, 2022

BySenti Biosciences

Manufacture of Carina’s LGR5 CAR-T has begun with CellVec contracted to produce GMP-grade lentivirus constructs

Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late 2022. Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a group of genes to a patient’s ...

Nov. 9, 2021

ByCarina Biotech

Employee Spotlight: Joana Murad Mabaera PhD

Joana Murad Mabaera, Executive Director of R&D Expertise: Cellular Therapies and Molecular Biomarkers What are your professional interests & in what ways does Celdara help you engage those interests? My core professional interest is translational science. At Celdara Medical, I help build the foundation for the development of early-stage innovation into life-changing treatment options. ...

Sep. 27, 2021

ByCeldara Medical, LLC

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you